Suicide gene therapy: Possible applications in haematopoietic disorders

Journal of Internal Medicine

Volumn 249, Issue 4, 2001, Pages 359-367

  Dilber, M S ^a,b   Gahrton, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bystander effect; Ganciclovir; Gene therapy; Herpes simplex virus thymidine kinase; Suicide gene; VP22

Indexed keywords

2 AMINOANTHRACENE; 4 HYDROPEROXYCYCLOPHOSPHAMIDE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 6 METHYLPURINE; ALKYLATING AGENT; AMYGDALIN; BETA GLUCOSIDASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B1; CYTOCHROME P450 4B1; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GANCICLOVIR DERIVATIVE; GANCICLOVIR TRIPHOSPHATE; GAP JUNCTION PROTEIN; GENE PRODUCT; GUANINE DERIVATIVE; HYDROXYLAMINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; NITROREDUCTASE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; TIOGUANINE; TIOGUANINE TRIPHOSPHATE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOGRAFT; AUTOGRAFT; BONE MARROW; BYSTANDER EFFECT; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL ACTIVATION; CONFERENCE PAPER; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; DNA MODIFICATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SENSITIVITY; EFFECTOR CELL; EPSTEIN BARR VIRUS; GAP JUNCTION; GENE CONSTRUCT; GENE INDUCTION; GENE THERAPY; GENE TRANSFER; GENETIC CODE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOMODULATION; LEUKEMIA; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SUICIDE GENE; SUICIDE GENE THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; CONNEXINS; CYTOSINE DEAMINASE; GENE THERAPY; HEMATOLOGIC NEOPLASMS; HUMANS; NUCLEOSIDE DEAMINASES; PRODRUGS; SIMPLEXVIRUS; THYMIDINE KINASE; VIRAL PROTEINS;

EID: 0035730284     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00808.x     Document Type: Conference Paper

References (74)

1. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control stratgy
2. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
3. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats
4. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA
5. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro drug sensitization system
6. Thymidine kinase obliteration: Creation of transgenic mice with controlled immune deficiency
7. In situ use of suicide genes for cancer therapy
8. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase
9. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
10. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory
11. Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer
12. Metabolic coupling, ionic coupling and cell contacts
13. Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine
14. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines
15. Potential of Varicella zoster virus thymidine kinase as a suicide gene in breast cancer cells
16. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)
17. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy
18. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol
19. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene
20. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow
21. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
22. 'Bystander killing' induces apoptosis and is inhibited by forskolin
23. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
24. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
25. In vivo analysis of the 'bystander effect': A cytokine cascade
26. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy
27. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro
28. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
29. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo
30. Projection structure of a gap junction membrane channel at 7 A resolution
31. Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap junctional plaques
32. Cell junction cyclic AMP: 1. Upregulation of junctional membrane permeability and junctional membrane particles by administration of cyclic nucleotide or phosphodiesterase inhibitor
33. Glutathione depletion potentiates 12-O-tetradecanoyl phorbol-13-acetate (TPA)-induced inhibition of gap junctional intercellular communication in WBF344 rat liver epithelial cells: Relationship to intracellular oxidative stress
34. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo
35. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
36. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
37. Suicide gene therapy for plasma cell tumors
38. HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect
39. Suicide genes and bystander killing: Local and distant effects
40. Differential regulation of gap junctions by proinflammatory mediators in vitro
41. Intercellular trafficking and protein delivery by a herpesvirus structural protein
42. The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49
43. A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted
44. Intercellular spread of GFP-VP22
45. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22
46. Catch VP22: The hitch-hiker's ride to gene therapy?
47. Adenovirus vector-based purging of multiple myeloma cells
48. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells
49. Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation
50. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation?
51. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir
52. Highly-efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin
53. Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements
54. Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic stem cell transplantation
55. Ex vivo T lymphocyte expansion for retroviral transduction. Influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution
56. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
57. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: A phase I-II study
58. "Suicide" gene for the control of graft-versus-host disease
59. Identification of a graft versus host disease-associated human minor histocompatibility antigen
60. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation
61. The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism
62. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
63. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
64. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1
65. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
66. Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant
67. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
68. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
69. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells
70. Hematological malignancies
71. Vaccinations with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant
72. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants
73. Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-alpha 1 and herpes simplex thymidine kinase followed by ganciclovir
74. Ganciclovir-mediated in vivo elimination of myeloid leukemic cells expressing the HSVtk gene induces HSVtk loss variants